Rivaroxaban vs. Aspirin After Total Hip or Knee Replacement

Aspirin was noninferior to rivaroxaban for preventing venous thromboembolism, and bleeding complications were similar.

To prevent venous thromboembolism (VTE) after total hip arthroplasty (THA) and total knee arthroplasty (TKA), guidelines from the American College of Chest Physicians endorse several alternatives: low-molecular-weight heparin, fondaparinux, direct-acting oral anticoagulants (apixaban [Eliquis], dabigatran [Pradaxa], or rivaroxaban [Xarelto]), low-dose unfractionated heparin, warfarin, or aspirin (Chest 2012; 141[2 Suppl]:e278S). In this Canadian double-blind, randomized, noninferiority trial that involved 3424 participants, two of these agents — aspirin and rivaroxaban — were compared directly. About half the participants underwent THA, and half underwent TKA.

All patients received rivaroxaban (10 mg daily) for the first 5 postoperative days…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Rivaroxaban vs. Aspirin After Total Hip or Knee Replacement

Topics

Reviewing Author